As lead­ing syn­bio play­ers bask in spot­light, US/Chi­na start­up lands $100M to find its own niche

4 years ago
Financing

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

4 years ago
Deals

As­traZeneca and Am­gen qui­et­ly ad­mit teze­pelum­ab set­back as the Dupix­ent chal­lenger heads to FDA

4 years ago
R&D

Flush with cash, Rakuten bil­lion­aire Mick­ey Mik­i­tani looks to take his pho­toim­munother­a­py plat­form glob­al

4 years ago
People
Financing

In­sulin biosim­i­lar wins first-ever in­ter­change­able des­ig­na­tion from FDA

4 years ago
Pharma
FDA+

Mer­ck and Pfiz­er back a Michi­gan star­tup's mis­sion to ad­vance tu­mor pro­fil­ing

4 years ago
Financing

Alzheimer's ad­comm mem­bers ques­tion FDA: How can you use amy­loid as the ba­sis for an ac­cel­er­at­ed ap­proval?

4 years ago
R&D

When a life-sav­ing vac­cine be­came a cash cow: Pfiz­er now projects $33.5B in Covid-19 vac­cine sales in 2021 alone

4 years ago
Pharma
Coronavirus

US sells Wu-Tang Clan al­bum to cov­er Shkre­li debt; Or­biMed backs GSK vet­s' Chi­nese start­up

4 years ago
News Briefing

Bris­tol My­er­s' Op­di­vo turns the boat around in Q2 as man­u­fac­tur­ing is­sues haunt CAR-T launch

4 years ago
Pharma

Covid-19 roundup: As­traZeneca pub­lish­es da­ta on blood clots as­so­ci­at­ed with vac­cine; Glax­o­SmithK­line and Vir ink mAb ...

4 years ago
Coronavirus

Glax­o­SmithK­line punts a key Ze­ju­la com­bo study in ovar­i­an can­cer with added set­backs on ICOS and RSV

4 years ago
R&D

NewAms­ter­dam Phar­ma res­ur­rects Am­gen's old CETP drug with plans to jump in­to PhI­II this year

4 years ago
R&D

In halt­ing con­fir­ma­to­ry tri­al for On­copep­tides' ac­cel­er­at­ed ap­proval, FDA notes in­creased risk of death

4 years ago
FDA+

One Ring to rule them all? Flag­ship’s big bet on dom­i­nat­ing gene ther­a­py 2.0 at­tracts a $117M megaround

4 years ago
R&D

Bio­gen push­es for broad CMS cov­er­age of Alzheimer's drug — while Eli Lil­ly looks to es­cape an NCD

4 years ago
Pharma

Deer­field and ARCH back a new $200M SPAC run by Cal­i­for­nia VC firm

4 years ago
Financing

As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

4 years ago
Financing
Deals

Deep Ge­nomics, now flush with cash, plans to take dozens of RNA ther­a­pies to the clin­ic

4 years ago
Financing
AI

In Cure­Vac's fail­ure, a pos­si­ble ver­dict on the past (and fu­ture) of mR­NA vac­cines

4 years ago
R&D
In Focus

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er ...

4 years ago
Deals

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug ...

4 years ago
Deals
R&D

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's ...

4 years ago
Financing
Deals

Mer­ck­'s wom­en's health spin­out snags mid-stage can­di­date for preterm birth; Keytru­da nails down TNBC ap­proval af­ter ...

4 years ago
News Briefing
First page Previous page 670671672673674675676 Next page Last page
A service from the Financial Times